We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Study to Compare Different Formulations of AZD3355

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00688402
Recruitment Status : Completed
First Posted : June 3, 2008
Last Update Posted : December 3, 2010
Sponsor:
Information provided by:

May 30, 2008
June 3, 2008
December 3, 2010
April 2008
June 2008   (Final data collection date for primary outcome measure)
Specific AE questions [ Time Frame: During 0-4 hours post dose ]
Same as current
Complete list of historical versions of study NCT00688402 on ClinicalTrials.gov Archive Site
  • PK variables [ Time Frame: Frequent sampling up to 36 hours post dose ]
  • Safety variables (other adverse events, blood pressure, pulse, safety lab) [ Time Frame: During the whole treatment period ]
Same as current
Not Provided
Not Provided
 
Study to Compare Different Formulations of AZD3355
A Double-blind, Randomized, Cross-over Design, Phase 1 Pharmacodynamic Study to Investigate the Effect of Different Formulations of AZD3355 for the Development of Paresthesiae After Dosing in Healthy Subjects
The purpose of the study is to compare different formulations of AZD3355 in regard to possible adverse events such as sensations of numbness, tinglings and heat in the skin.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Gastroesophageal Reflux Disease
Drug: AZD3355
Single dose
Other Name: Lesogaberan
  • Experimental: 1
    IR Formulation 65 mg
    Intervention: Drug: AZD3355
  • Experimental: 2
    IR Formulation 150 mg
    Intervention: Drug: AZD3355
  • Experimental: 3
    MR formulation, 1h 65 mg
    Intervention: Drug: AZD3355
  • Experimental: 4
    MR Formulation, 1h 150 mg
    Intervention: Drug: AZD3355
  • Experimental: 5
    MR Formulation, 2h 150 mg
    Intervention: Drug: AZD3355
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
48
June 2008
June 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Provision of written informed consent
  • Female subjects with no childbearing potentials or using highly efficient contraceptive methods
  • Clinically normal physical findings

Exclusion Criteria:

  • Clinically significant illness within 2 weeks prior to the first dose of investigational product
  • History of clinically significant disease
  • Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product
Sexes Eligible for Study: All
18 Years to 45 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Sweden
 
 
NCT00688402
D9120C00031
EudraCT nr 2007-007126-22
No
Not Provided
Not Provided
Debra G. Silberg, MD, PhD, Medical Science Director, AZD3355, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Study Director: Eva Ersdal, PhD AstraZeneca R&d, Mölndal, Sweden
Principal Investigator: Aslak Rautio, MD Quintiles Hermelinen, Varvsgatan 53, SE-972 33 Luleå, Sweden
AstraZeneca
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP